In the last few days researchers from the Vaccine Research Center at the US NIH released a paper for peer review on the performance of a new mRNA vaccine targeting Omicron variant, delivered as a ‘booster’ after two doses of mRNA vaccine targeting the original Wuhan strain (ie, the current type of covid vaccine).
The US NIH state that OAS is a likely…
In the last few days researchers from the Vaccine Research Center at the US NIH released a paper for peer review on the performance of a new mRNA vaccine targeting Omicron variant, delivered as a ‘booster’ after two doses of mRNA vaccine targeting the original Wuhan strain (ie, the current type of covid vaccine).
Create your profile
Only paid subscribers can comment on this post
Check your email
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to sign in.